Treatment of “Poor Risk” Acute Myeloid Leukemia with Fludarabine, Cytarabine and G-CSF (Flag Regimen): A Single Center Study

References

• Lowenberg B., Downing J. R., Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051–1062
   PubMed Web of Science ®Google Scholar
• Freireich E. Arabinosyl cytosine: a 20 year update. J Clin Oncol 1987; 5: 523–524
   PubMed Web of Science ®Google Scholar
• Cole N., Gibson B. E. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia. Blood Rewievs 1997; 11: 39–45
   PubMed Web of Science ®Google Scholar
• Capizzi R. L., Powell B. L. Sequential high dose ara-C and asparaginase versus high dose ara-C alone in the treatment of patients with relapsed and refractory acute leukemias. Sem Onc 1987; 114(Suppl 1)40–50
   Google Scholar
• Hiddemann W., Kreutzmann H., Straif K. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 1987; 69: 744–749
   PubMed Web of Science ®Google Scholar
• Carella A. M., Carlier P., Pungolino E., Resegotti L., Liso V., Stasi R., Montillo M., Iacopino P., Mirto S., GIMEMA group. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. Leukemia 1993; 7: 196–199
   PubMed Web of Science ®Google Scholar
• Hines J. D., Oken M. M., Mazza J. J. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute non-lymphocytic leukemia. J Clin Oncol 1984; 2: 545–549
   PubMed Web of Science ®Google Scholar
• Herzig R. H., Wolff S. N., Lazarus H. M. High dose cytosine arabinoside in the treatment of refractory leukaemia. Blood 1983; 62: 361–369
   PubMed Web of Science ®Google Scholar
• Amadori S., Arcese W., Isacchi G., Meloni G., Petti M. C., Monarca B., Testi A. M., Mandelli F. Mitoxantrone, etoposide and intermediate dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 1991; 9: 1210–1214
   PubMed Web of Science ®Google Scholar
• Keating M., Kantarjian H., O'Brien S., Roller C., Talpaz M., Schachner J., Childs C., Freireich E., McCredie K. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991; 9: 44–49
   PubMed Web of Science ®Google Scholar
• Warrell R., Berman E. Phase 1 and 2 study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 1986; 4: 74–79
   PubMed Web of Science ®Google Scholar
• Chun H., Leyland-Jones B., Caryk S., Hoth D. Central nervous system toxicity of fludarabine phosphate. Cane Treat Rept 1986; 70: 1225–1228
   PubMedGoogle Scholar
• Estey E., Plunkett W., Ghandi V., Rios M., Kantarjian H., Keating M. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymph 1993; 9: 343–350
   PubMed Web of Science ®Google Scholar
• Ghandi V., Estey E., Keating M., Plunkett W. Fludarabine potentiates metabolism of cytarabine in patient with acute myelogenous leukemia during therapy. J Clin Onc 1993; 11: 116–124
   PubMed Web of Science ®Google Scholar
• Estey E., Thall P., Andreef M., Beran M., Kantarjian H., O'Brien S., Escudier S., Robertson L. E., Koller C., Kornblau Pierce S., Freireich S., Deisseroth E., Keating A. M. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony stimulating factor. J Clin Oncol 1994; 12: 671–678
   PubMed Web of Science ®Google Scholar
• Tosi P., Visani G., Ottaviani E., Manfroi S., Zinzani P., Tura S. Fludarabine plus ara-C + G-CSF-cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia 1994; 8: 2076–2082
   PubMed Web of Science ®Google Scholar
• Tafuri A., Andreef M. Kinetic rationale for cytokine induced recruitment of myeloblastic leukemia followed by cycle specific chemotherapy in vitro. Leukemia 1990; 4: 826–34
   PubMed Web of Science ®Google Scholar
• Tafuri A., De Felice L., Petrucci M., Mascolo M., Ricciardi M., Ciliberti C., Martelli M., Petti M. Multidrug resistance expression and proliferative studies in poor risk acute myeloid leukemia treated with the FLAG (G-CSF plus Fludarabine and ARA-C) regimen. Cyto Mol Ther 1995; 1: 301–307
   PubMedGoogle Scholar
• Visani G., Tosi P., Zinzani P. L., Manfroi S., Ottaviani E., Testoni N., Clavio M., Cenacchi A., Gamberi B., Carrar P., Gobbi M., Tura S. FLAG (Fludarabine + High-dose Cytrabine + G-CSF): an effective and tolerable protocol for the treatment og “poor-risk” acute myeloid leukemias. Leukemia 1994; 8: 1842–1846
   PubMed Web of Science ®Google Scholar
• Montillo M., Mirto S., Petti M. C., Latagliata R., Magrin S., Pinto A., Zagonel V., Mele G., Tedeschi A., Ferrara F. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 1998; 58: 105–109
   PubMed Web of Science ®Google Scholar
• Clavio M., Carrara P., Miglino M., Pierri I., Canepa L., Balleari E., Gatti A. M., Cent P., Celesti L., Vallebella E., Sessarego M., Patrone F., Ghio R., Gobbi M. High efficacy of fludarabine containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 1996; 81: 512–519
   Google Scholar
• Cascavilla N., Melillo L., D'Arena G., Greco M. M., Carella A. M., Sajeva M. R., Perla G., Matera R., Minervini M. M., Carotenuto M. Minimally differentiated acute myeloid leukemia (AML M0): clinico-biological findings of 29 cases. Leuk Lymph 2000; 37: 105–113
   PubMed Web of Science ®Google Scholar
• Byrne J. L., Dasgupta E., Palis M., Turzanski J., Forman K., Mitchell D., Haynes A. P., Russell N. H. Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG. Leukemia 1999; 13: 786–791
   PubMed Web of Science ®Google Scholar
• Parker J. E., Pagliuca A., Mijovic A., Cullis J. O., Czepulkowski B., Rassam S. M., Samaratunga I. R., Grace R., Gover P. A., Mufti G. J. Fludarabine, cytarabine, G-CSF and Idarubicin (FLAG-IDA) for the treatment of poor risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 1997; 99: 939–944
   PubMed Web of Science ®Google Scholar
• Carella A. M., Cascavilla N., Greco M. M., Melillo L., Sajeva M. R., D'Arena G., Carotenuto M. FLAG protocol for acute myeloid leukemia at onset in elderly. Haematologica 1999; 84(Suppl 9)81–82
   Google Scholar
• Deane M., Koh M., Foroni L., Galactowicz G., Hoffbrand A. U., Lawler M., Secker-Walker L., Prentice H. G. FLAG-idarubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission. Bone Marrow Transpl 1998; 22: 1137–1143
   PubMed Web of Science ®Google Scholar
• Visani G., Tosi P., Zinzani P. L., Manfroi S., Ottaviani F., Cenacchi A., Carrara P., Clavio M., Gobbi M., Tura S. FLAG (Fludarabine, Cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects. Eur J Haematol 1996; 56: 308–312
   PubMed Web of Science ®Google Scholar
• Montillo M., Tedeschi A., Centurioni R., Leoni P. Treatment of relapsed acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony stimulating factor (FLAG-G-CSF). Leuk Lymph 1997; 25: 579–582
   PubMed Web of Science ®Google Scholar
• Visani G., Tosi P., Zinzani P. L., Manfroi S., Zaccaria A., Testoni N., Lemoli G., Rosti G., Pelliconi S., Tura S. FLAG (Fludarabine + Cytosine arabinoside + G-CSF) induces complete remission in acute phase chronic myeloid leukemia: a case report. Br J Haematol 1994; 86: 394–396
   PubMed Web of Science ®Google Scholar